Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 79 entries
Sorted by: Best Match Show Resources per page
12 articles of 1926.

Archives of disease in childhood

Forfar JO, Mowat AP, Clarke CA, Chiswick ML, Gordon N, McNeish AS, Booth IW, Bower BD, Arneil GC, Walker-Smith JA, Smithells RW, Wigglesworth JS, Robinson RJ.
PMID: 21032750
Arch Dis Child. 1986 Oct;61(10):939-65. doi: 10.1136/adc.61.10.939.

No abstract available.

Cite
Forfar JO, Mowat AP, Clarke CA, et al. 12 articles of 1926. Arch Dis Child. 1986;61(10):939-65doi: 10.1136/adc.61.10.939.
Forfar, J. O., Mowat, A. P., Clarke, C. A., Chiswick, M. L., Gordon, N., McNeish, A. S., Booth, I. W., Bower, B. D., Arneil, G. C., Walker-Smith, J. A., Smithells, R. W., Wigglesworth, J. S., & Robinson, R. J. (1986). 12 articles of 1926. Archives of disease in childhood, 61(10), 939-65. https://doi.org/10.1136/adc.61.10.939
Forfar, J O, et al. "12 articles of 1926." Archives of disease in childhood vol. 61,10 (1986): 939-65. doi: https://doi.org/10.1136/adc.61.10.939
Forfar JO, Mowat AP, Clarke CA, Chiswick ML, Gordon N, McNeish AS, Booth IW, Bower BD, Arneil GC, Walker-Smith JA, Smithells RW, Wigglesworth JS, Robinson RJ. 12 articles of 1926. Arch Dis Child. 1986 Oct;61(10):939-65. doi: 10.1136/adc.61.10.939. PMID: 21032750; PMCID: PMC1777966.
Copy Download .nbib Format: NLM
Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.

Scientific reports

Walton JB, Farquharson M, Mason S, Port J, Kruspig B, Dowson S, Stevenson D, Murphy D, Matzuk M, Kim J, Coffelt S, Blyth K, McNeish IA.
PMID: 29651149
Sci Rep. 2018 Apr 13;8(1):6231. doi: 10.1038/s41598-018-24099-3.

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.

Cite
Walton JB, Farquharson M, Mason S, et al. Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Sci Rep. 2018;8(1):6231doi: 10.1038/s41598-018-24099-3.
Walton, J. B., Farquharson, M., Mason, S., Port, J., Kruspig, B., Dowson, S., Stevenson, D., Murphy, D., Matzuk, M., Kim, J., Coffelt, S., Blyth, K., & McNeish, I. A. (2018). Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific reports, 8(1), 6231. https://doi.org/10.1038/s41598-018-24099-3
Walton, Josephine B, et al. "Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity." Scientific reports vol. 8,1 (2018): 6231. doi: https://doi.org/10.1038/s41598-018-24099-3
Walton JB, Farquharson M, Mason S, Port J, Kruspig B, Dowson S, Stevenson D, Murphy D, Matzuk M, Kim J, Coffelt S, Blyth K, McNeish IA. Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Sci Rep. 2018 Apr 13;8(1):6231. doi: 10.1038/s41598-018-24099-3. PMID: 29651149; PMCID: PMC5897571.
Copy Download .nbib Format: NLM
Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.

Oncotarget

McGivern N, El-Helali A, Mullan P, McNeish IA, Paul Harkin D, Kennedy RD, McCabe N.
PMID: 29435137
Oncotarget. 2017 Dec 20;9(4):4722-4736. doi: 10.18632/oncotarget.23524. eCollection 2018 Jan 12.

SRC tyrosine kinase is frequently overexpressed and activated in late-stage, poor prognosis ovarian tumours, and preclinical studies have supported the use of targeted SRC inhibitors in the treatment of this disease. The SAPPROC trial investigated the addition of the...

Cite
McGivern N, El-Helali A, Mullan P, et al. Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. Oncotarget. 2017;9(4):4722-4736doi: 10.18632/oncotarget.23524.
McGivern, N., El-Helali, A., Mullan, P., McNeish, I. A., Paul Harkin, D., Kennedy, R. D., & McCabe, N. (2018). Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. Oncotarget, 9(4), 4722-4736. https://doi.org/10.18632/oncotarget.23524
McGivern, Niamh, et al. "Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer." Oncotarget vol. 9,4 (2018): 4722-4736. doi: https://doi.org/10.18632/oncotarget.23524
McGivern N, El-Helali A, Mullan P, McNeish IA, Paul Harkin D, Kennedy RD, McCabe N. Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. Oncotarget. 2017 Dec 20;9(4):4722-4736. doi: 10.18632/oncotarget.23524. eCollection 2018 Jan 12. PMID: 29435137; PMCID: PMC5797008.
Copy Download .nbib Format: NLM
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448].

Gynecologic oncology

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF, Singh N.
PMID: 32087992
Gynecol Oncol. 2020 May;157(2):558-559. doi: 10.1016/j.ygyno.2020.02.023. Epub 2020 Feb 20.

No abstract available.

Cite
Cohen PA, Powell A, Böhm S, et al. Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]. Gynecol Oncol. 2020;157(2):558-559doi: 10.1016/j.ygyno.2020.02.023.
Cohen, P. A., Powell, A., Böhm, S., Gilks, C. B., Stewart, C. J. R., Meniawy, T. M., Bulsara, M., Avril, S., Brockbank, E. C., Bosse, T., de Azevedo Focchi, G. R., Ganesan, R., Glasspool, R. M., Howitt, B. E., Kim, H. S., Lee, J. Y., Le, N. D., Lockley, M., Manchanda, R., Mandalia, T., McCluggage, W. G., McNeish, I., Midha, D., Srinivasan, R., Tan, Y. Y., van der Griend, R., Yunokawa, M., Zannoni, G. F., & Singh, N. (2020). Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]. Gynecologic oncology, 157(2), 558-559. https://doi.org/10.1016/j.ygyno.2020.02.023
Cohen, Paul A, et al. "Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]." Gynecologic oncology vol. 157,2 (2020): 558-559. doi: https://doi.org/10.1016/j.ygyno.2020.02.023
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF, Singh N. Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]. Gynecol Oncol. 2020 May;157(2):558-559. doi: 10.1016/j.ygyno.2020.02.023. Epub 2020 Feb 20. PMID: 32087992.
Copy Download .nbib Format: NLM
NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer.

Molecular therapy oncolytics

Leung EYL, Ennis DP, Kennedy PR, Hansell C, Dowson S, Farquharson M, Spiliopoulou P, Nautiyal J, McNamara S, Carlin LM, Fisher K, Davis DM, Graham G, McNeish IA.
PMID: 32195317
Mol Ther Oncolytics. 2020 Feb 15;16:289-301. doi: 10.1016/j.omto.2020.02.001. eCollection 2020 Mar 27.

Oncolytic viruses (OVs) can trigger profound innate and adaptive immune responses, which have the potential both to potentiate and reduce the activity of OVs. Natural killer (NK) cells can mediate potent anti-viral and anti-tumoral responses, but there are no...

Cite
Leung EYL, Ennis DP, Kennedy PR, et al. NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer. Mol Ther Oncolytics. 2020;16:289-301doi: 10.1016/j.omto.2020.02.001.
Leung, E. Y. L., Ennis, D. P., Kennedy, P. R., Hansell, C., Dowson, S., Farquharson, M., Spiliopoulou, P., Nautiyal, J., McNamara, S., Carlin, L. M., Fisher, K., Davis, D. M., Graham, G., & McNeish, I. A. (2020). NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer. Molecular therapy oncolytics, 16289-301. https://doi.org/10.1016/j.omto.2020.02.001
Leung, Elaine Y L, et al. "NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer." Molecular therapy oncolytics vol. 16 (2020): 289-301. doi: https://doi.org/10.1016/j.omto.2020.02.001
Leung EYL, Ennis DP, Kennedy PR, Hansell C, Dowson S, Farquharson M, Spiliopoulou P, Nautiyal J, McNamara S, Carlin LM, Fisher K, Davis DM, Graham G, McNeish IA. NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer. Mol Ther Oncolytics. 2020 Feb 15;16:289-301. doi: 10.1016/j.omto.2020.02.001. eCollection 2020 Mar 27. PMID: 32195317; PMCID: PMC7068056.
Copy Download .nbib Format: NLM
Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations.

Critical reviews in oncology/hematology

Tamburin S, Park SB, Schenone A, Mantovani E, Hamedani M, Alberti P, Yildiz-Kabak V, Kleckner IR, Kolb N, Mazzucchelli M, McNeish BL, Argyriou AA, Cavaletti G, Hoke A.
PMID: 34968623
Crit Rev Oncol Hematol. 2021 Dec 28;103575. doi: 10.1016/j.critrevonc.2021.103575. Epub 2021 Dec 28.

Pharmacological strategies for chemotherapy-induced peripheral neurotoxicity (CIPN) are very limited. We systematically reviewed data on rehabilitation, exercise, physical therapy, and other physical non-pharmacological interventions and offered evidence-based recommendations for the prevention and treatment of CIPN. A literature search using...

Cite
Tamburin S, Park SB, Schenone A, et al. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Crit Rev Oncol Hematol. 2021;103575doi: 10.1016/j.critrevonc.2021.103575.
Tamburin, S., Park, S. B., Schenone, A., Mantovani, E., Hamedani, M., Alberti, P., Yildiz-Kabak, V., Kleckner, I. R., Kolb, N., Mazzucchelli, M., McNeish, B. L., Argyriou, A. A., Cavaletti, G., Hoke, A. (2021). Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Critical reviews in oncology/hematology, 103575. https://doi.org/10.1016/j.critrevonc.2021.103575
Tamburin, Stefano, et al. "Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations." Critical reviews in oncology/hematology vol. (2021): 103575. doi: https://doi.org/10.1016/j.critrevonc.2021.103575
Tamburin S, Park SB, Schenone A, Mantovani E, Hamedani M, Alberti P, Yildiz-Kabak V, Kleckner IR, Kolb N, Mazzucchelli M, McNeish BL, Argyriou AA, Cavaletti G, Hoke A. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Crit Rev Oncol Hematol. 2021 Dec 28;103575. doi: 10.1016/j.critrevonc.2021.103575. Epub 2021 Dec 28. PMID: 34968623.
Copy Download .nbib Format: NLM
Second-by-second infant and mother emotion regulation and coregulation processes.

Development and psychopathology

Somers JA, Luecken LJ, McNeish D, Lemery-Chalfant K, Spinrad TL.
PMID: 34210378
Dev Psychopathol. 2021 Jul 02;1-14. doi: 10.1017/S0954579421000389. Epub 2021 Jul 02.

Context-appropriate infant physiological functioning may support emotion regulation and mother-infant emotion coregulation. Among a sample of 210 low-income Mexican-origin mothers and their 24-week-old infants, dynamic structural equation modeling (DSEM) was used to examine whether within-infant vagal functioning accounted for...

Cite
Somers JA, Luecken LJ, McNeish D, et al. Second-by-second infant and mother emotion regulation and coregulation processes. Dev Psychopathol. 2021;1-14doi: 10.1017/S0954579421000389.
Somers, J. A., Luecken, L. J., McNeish, D., Lemery-Chalfant, K., & Spinrad, T. L. (2021). Second-by-second infant and mother emotion regulation and coregulation processes. Development and psychopathology, 1-14. https://doi.org/10.1017/S0954579421000389
Somers, Jennifer A, et al. "Second-by-second infant and mother emotion regulation and coregulation processes." Development and psychopathology vol. (2021): 1-14. doi: https://doi.org/10.1017/S0954579421000389
Somers JA, Luecken LJ, McNeish D, Lemery-Chalfant K, Spinrad TL. Second-by-second infant and mother emotion regulation and coregulation processes. Dev Psychopathol. 2021 Jul 02;1-14. doi: 10.1017/S0954579421000389. Epub 2021 Jul 02. PMID: 34210378.
Copy Download .nbib Format: NLM
Facilitating Growth Mixture Model Convergence in Preventive Interventions.

Prevention science : the official journal of the Society for Prevention Research

McNeish D, Peña A, Vander Wyst KB, Ayers SL, Olson ML, Shaibi GQ.
PMID: 34235633
Prev Sci. 2021 Jul 07; doi: 10.1007/s11121-021-01262-3. Epub 2021 Jul 07.

Growth mixture models (GMMs) are applied to intervention studies with repeated measures to explore heterogeneity in the intervention effect. However, traditional GMMs are known to be difficult to estimate, especially at sample sizes common in single-center interventions. Common strategies...

Cite
McNeish D, Peña A, Vander Wyst KB, et al. Facilitating Growth Mixture Model Convergence in Preventive Interventions. Prev Sci. 2021;doi: 10.1007/s11121-021-01262-3.
McNeish, D., Peña, A., Vander Wyst, K. B., Ayers, S. L., Olson, M. L., & Shaibi, G. Q. (2021). Facilitating Growth Mixture Model Convergence in Preventive Interventions. Prevention science : the official journal of the Society for Prevention Research, . https://doi.org/10.1007/s11121-021-01262-3
McNeish, Daniel, et al. "Facilitating Growth Mixture Model Convergence in Preventive Interventions." Prevention science : the official journal of the Society for Prevention Research vol. (2021). doi: https://doi.org/10.1007/s11121-021-01262-3
McNeish D, Peña A, Vander Wyst KB, Ayers SL, Olson ML, Shaibi GQ. Facilitating Growth Mixture Model Convergence in Preventive Interventions. Prev Sci. 2021 Jul 07; doi: 10.1007/s11121-021-01262-3. Epub 2021 Jul 07. PMID: 34235633.
Copy Download .nbib Format: NLM
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marmé F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS.
PMID: 34593565
Int J Gynecol Cancer. 2021 Dec;31(12):1589-1594. doi: 10.1136/ijgc-2021-002933. Epub 2021 Sep 30.

BACKGROUND: The optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance treatment in the frontline setting versus active surveillance....

Cite
Monk BJ, Coleman RL, Fujiwara K, et al. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021;31(12):1589-1594doi: 10.1136/ijgc-2021-002933.
Monk, B. J., Coleman, R. L., Fujiwara, K., Wilson, M. K., Oza, A. M., Oaknin, A., O'Malley, D. M., Lorusso, D., Westin, S. N., Safra, T., Herzog, T. J., Marmé, F., N Eskander, R., Lin, K. K., Shih, D., Goble, S., Grechko, N., Hume, S., Maloney, L., McNeish, I. A., & Kristeleit, R. S. (2021). ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 31(12), 1589-1594. https://doi.org/10.1136/ijgc-2021-002933
Monk, Bradley J, et al. "ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 31,12 (2021): 1589-1594. doi: https://doi.org/10.1136/ijgc-2021-002933
Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marmé F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021 Dec;31(12):1589-1594. doi: 10.1136/ijgc-2021-002933. Epub 2021 Sep 30. PMID: 34593565.
Copy Download .nbib Format: NLM
Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations.

Critical reviews in oncology/hematology

Tamburin S, Park SB, Schenone A, Mantovani E, Hamedani M, Alberti P, Yildiz-Kabak V, Kleckner IR, Kolb N, Mazzucchelli M, McNeish B, Argyriou AA, Cavaletti G, Hoke A.
PMID: 34968623
Crit Rev Oncol Hematol. 2021 Dec 27;103575. doi: 10.1016/j.critrevonc.2021.103575. Epub 2021 Dec 27.

Pharmacological strategies for chemotherapy-induced peripheral neurotoxicity (CIPN) are very limited. We systematically reviewed data on rehabilitation, exercise, physical therapy, and other physical non-pharmacological interventions and offered evidence-based recommendations for the prevention and treatment of CIPN. A literature search using...

Cite
Tamburin S, Park SB, Schenone A, et al. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations. Crit Rev Oncol Hematol. 2021;103575doi: 10.1016/j.critrevonc.2021.103575.
Tamburin, S., Park, S. B., Schenone, A., Mantovani, E., Hamedani, M., Alberti, P., Yildiz-Kabak, V., Kleckner, I. R., Kolb, N., Mazzucchelli, M., McNeish, B., Argyriou, A. A., Cavaletti, G., Hoke, A. (2021). Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations. Critical reviews in oncology/hematology, 103575. https://doi.org/10.1016/j.critrevonc.2021.103575
Tamburin, Stefano, et al. "Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations." Critical reviews in oncology/hematology vol. (2021): 103575. doi: https://doi.org/10.1016/j.critrevonc.2021.103575
Tamburin S, Park SB, Schenone A, Mantovani E, Hamedani M, Alberti P, Yildiz-Kabak V, Kleckner IR, Kolb N, Mazzucchelli M, McNeish B, Argyriou AA, Cavaletti G, Hoke A. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations. Crit Rev Oncol Hematol. 2021 Dec 27;103575. doi: 10.1016/j.critrevonc.2021.103575. Epub 2021 Dec 27. PMID: 34968623.
Copy Download .nbib Format: NLM
A primer on two-level dynamic structural equation models for intensive longitudinal data in Mplus.

Psychological methods

McNeish D, Hamaker EL.
PMID: 31855015
Psychol Methods. 2020 Oct;25(5):610-635. doi: 10.1037/met0000250. Epub 2019 Dec 19.

Technological advances have led to an increase in intensive longitudinal data and the statistical literature on modeling such data is rapidly expanding, as are software capabilities. Common methods in this area are related to time-series analysis, a framework that...

Cite
McNeish D, Hamaker EL. A primer on two-level dynamic structural equation models for intensive longitudinal data in Mplus. Psychol Methods. 2019;25(5):610-635doi: 10.1037/met0000250.
McNeish, D., & Hamaker, E. L. (2020). A primer on two-level dynamic structural equation models for intensive longitudinal data in Mplus. Psychological methods, 25(5), 610-635. https://doi.org/10.1037/met0000250
McNeish, Daniel, and Hamaker, Ellen L. "A primer on two-level dynamic structural equation models for intensive longitudinal data in Mplus." Psychological methods vol. 25,5 (2020): 610-635. doi: https://doi.org/10.1037/met0000250
McNeish D, Hamaker EL. A primer on two-level dynamic structural equation models for intensive longitudinal data in Mplus. Psychol Methods. 2020 Oct;25(5):610-635. doi: 10.1037/met0000250. Epub 2019 Dec 19. PMID: 31855015.
Copy Download .nbib Format: NLM
Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting.

Therapeutic advances in medical oncology

Tookman L, Krell J, Nkolobe B, Burley L, McNeish IA.
PMID: 32523631
Ther Adv Med Oncol. 2020 May 27;12:1758835920921980. doi: 10.1177/1758835920921980. eCollection 2020.

The use of targeted therapeutics known as poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for...

Cite
Tookman L, Krell J, Nkolobe B, et al. Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Ther Adv Med Oncol. 2020;12:1758835920921980doi: 10.1177/1758835920921980.
Tookman, L., Krell, J., Nkolobe, B., Burley, L., & McNeish, I. A. (2020). Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Therapeutic advances in medical oncology, 121758835920921980. https://doi.org/10.1177/1758835920921980
Tookman, Laura, et al. "Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting." Therapeutic advances in medical oncology vol. 12 (2020): 1758835920921980. doi: https://doi.org/10.1177/1758835920921980
Tookman L, Krell J, Nkolobe B, Burley L, McNeish IA. Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Ther Adv Med Oncol. 2020 May 27;12:1758835920921980. doi: 10.1177/1758835920921980. eCollection 2020. PMID: 32523631; PMCID: PMC7257860.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 79 entries